Chinese patients are expected to be able to buy 14 kinds of cancer drugs at a lower price from September, according to China's state medical insurance administration.
The drugs are all crucial in dealing with haematological neoplasms and solid tumours, and have great clinical value and huge benefits for patients, the National Healthcare Security Administration said.
It asked pharmaceutical companies to adhere to the price cut in line with the lowered procurement prices of these drugs, Xinhua news agency reported.
A range of several more drugs have been selected to be included in the medical insurance reimbursement list later.
--IANS
in/
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app